Antenatal Dexamethasone for Early Preterm Birth in Low-Resource Countries.

BACKGROUND: The safety and efficacy of antenatal glucocorticoids in women in low-resource countries who are at risk for preterm birth are uncertain. METHODS: We conducted a multicountry, randomized trial involving pregnant women between 26 weeks 0 days and 33 weeks 6 days of gestation who were at risk for preterm birth. The participants were assigned to intramuscular dexamethasone or identical placebo. The primary outcomes were neonatal death alone, stillbirth or neonatal death, and possible maternal bacterial infection; neonatal death alone and stillbirth or neonatal death were evaluated with superiority analyses, and possible maternal bacterial infection was evaluated with a noninferiority analysis with the use of a prespecified margin of 1.25 on the relative scale. RESULTS: A total of 2852 women (and their 3070 fetuses) from 29 secondary- and tertiary-level hospitals across Bangladesh, India, Kenya, Nigeria, and Pakistan underwent randomization. The trial was stopped for benefit at the second interim analysis. Neonatal death occurred in 278 of 1417 infants (19.6%) in the dexamethasone group and in 331 of 1406 infants (23.5%) in the placebo group (relative risk, 0.84; 95% confidence interval [CI], 0.72 to 0.97; P = 0.03). Stillbirth or neonatal death occurred in 393 of 1532 fetuses and infants (25.7%) and in 444 of 1519 fetuses and infants (29.2%), respectively (relative risk, 0.88; 95% CI, 0.78 to 0.99; P = 0.04); the incidence of possible maternal bacterial infection was 4.8% and 6.3%, respectively (relative risk, 0.76; 95% CI, 0.56 to 1.03). There was no significant between-group difference in the incidence of adverse events. CONCLUSIONS: Among women in low-resource countries who were at risk for early preterm birth, the use of dexamethasone resulted in significantly lower risks of neonatal death alone and stillbirth or neonatal death than the use of placebo, without an increase in the incidence of possible maternal bacterial infection. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization; Australian and New Zealand Clinical Trials Registry number, ACTRN12617000476336; Clinical Trials Registry-India number, CTRI/2017/04/008326.).

Predictive Value of Total Serum Bilirubin within 6 Hour of Birth for the Development of Hyperbilirubinemia After 72 hours of Birth.

INTRODUCTION: Neonatal jaundice is benign and no intervention might be required, but jaundice can be associated with an underlying disease condition, which therefore warrants accurate and unbiased estimation of bilirubin. Total Serum Bilirubin (TSB) measurements (at discharge between 18 hours and 72 hours) can be used to predict the chances of developing severe hyperbilirubinemia. MATERIALS AND METHODS: The present hospital-based prospective study was undertaken to determine the predictive value of serum bilirubin before 6 hours of life for subsequent hyperbilirubinemia in healthy term neonates. One hundred and fifty healthy term newborns delivered during January 2013-December 2013 at Hanagal Shri Kumareshwara Hospital and Research Centre, S. Nijalingappa Medical College, Bagalkot Karnataka, India, were included in the study. Serum bilirubin levels were estimated twice, first, within 6 hours of life and second, after 72 hours of life. Bilirubin values were plotted on previously published nomograms. Sensitivity, specificity of the test was established. RESULTS: A measure of TSB levels (within 6 hours of life) across the study population, showed that maximum number of infants (70/150) had TSB level between 4.1 and 5.5 mg/dL and 16 infants had TSB level >5.6 mg/dL. The TSB levels (after 72 hours of life) showed that maximum newborns (83/150) had TSB levels between 12.8 and 15.3 mg/dL and 9 infants had TSB levels between 7.7 and 10.2mg/dL. Eighteen infants developed hyperbilirubinemia. Newborns with TSB value of >4.95mg/dL within 6hours of life had developed significant hyperbilirubinemia after 72 hours of life with sensitivity of 100% and specificity of 89% (p=0.0001), which was highly statistically significant. CONCLUSION: A TSB level of >5 mg/dL within 6 hours of birth would serve as a predictor for risk of subsequent hyperbilirubinemia in the near future.

Clinico-laboratory profile of pediatric HIV in Karnataka.

OBJECTIVE: To study the clinical manifestations and incidence of opportunistic infections in HIV/AIDS seropositive proven hospitalized children. METHODS: Proven HIV seropositive children aged between 18 months to 12 years, admitted between April 2004 to June 2005 (15 months) to pediatric medical ward, KIMS, Hubli, were enrolled. Socio-demographic characteristics and clinical manifestations were recorded in the predesigned proforma. A complete physical examination and laboratory investigations were performed at the time of admission. Children were categorized as per 1994 revised CDC classification of pediatric HIV infection. RESULTS: Number of HIV seropositive children admitted during study period was 71. Vertical transmission was noted in 94.37%, which is the major route of transmission. The common symptoms noted were persistent fever (70.42%), persistent cough (59.15%), loss of appetite (59.15%), loss of weight (56.33%) and recurrent diarrhea (30.99%). The common signs present were, hepatomegaly (69.04%), skin lesions (59.15%), lymphadenopathy (57.75%) and severe malnutrition (54.93%). The common opportunistic infections observed were tuberculosis (38.03%), recurrent diarrhea (30.99%), oral candidiasis (21.13%) and recurrent bacterial pneumonia (12.68%). Six (8.45%) children died during the study period, which included 4 (5.63%) cases of HIV-encephalopathy. CONCLUSION: Vertical transmission was the major route of HIV infection. Persistent fever, cough, loss of appetite and loss of weight were common presenting clinical features. Tuberculosis was the commonest opportunistic infection.